新组合疗法在治疗复发性卵泡淋巴瘤方面显示出高效率,反应率为96%. New combo therapy shows high efficacy in treating relapsed follicular lymphoma, with 96% response rate.

一项新的研究表明,一种混合疗法 -- -- Epcoritamab + lenalidomide 和 rituximab -- -- 可能有效治疗复发性或复发性子宫淋巴瘤。 A new study shows that a combination therapy, epcoritamab plus lenalidomide and rituximab, may effectively treat relapsed or refractory follicular lymphoma. 试验报告,111名病人的总体答复率为96%,完整答复率为87%,两年总存活率为90%。 The trial reported an overall response rate of 96% and a complete response rate of 87% among 111 patients, with a two-year overall survival rate of 90%. 美国食品和药物管理局授予治疗突破地位,强调其作为这类癌症的有力治疗选择的潜力。 The U.S. FDA has granted the therapy breakthrough status, highlighting its potential as a strong treatment option for this type of cancer.